Oppenheimer Asset Management Inc. Purchases New Stake in HealthEquity, Inc. $HQY

Oppenheimer Asset Management Inc. acquired a new position in HealthEquity, Inc. (NASDAQ:HQY) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 233,378 shares of the company’s stock, valued at approximately $21,079,000.

Several other hedge funds have also recently bought and sold shares of the business. Acumen Wealth Advisors LLC purchased a new position in HealthEquity during the 4th quarter valued at about $27,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after purchasing an additional 293 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of HealthEquity in the fourth quarter worth approximately $28,000. Leonteq Securities AG lifted its position in shares of HealthEquity by 159.9% in the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after purchasing an additional 235 shares in the last quarter. Finally, Axiom Investment Management LLC acquired a new stake in shares of HealthEquity during the first quarter worth approximately $33,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 3,142 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $95.00, for a total transaction of $298,490.00. Following the transaction, the executive vice president owned 59,113 shares in the company, valued at $5,615,735. This trade represents a 5.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of HealthEquity stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $219,510.00. Following the completion of the transaction, the director directly owned 19,733 shares in the company, valued at approximately $1,775,970. This represents a 11.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 17,905 shares of company stock valued at $1,651,280. Corporate insiders own 1.60% of the company’s stock.

HealthEquity Price Performance

NASDAQ HQY opened at $104.73 on Friday. HealthEquity, Inc. has a fifty-two week low of $72.76 and a fifty-two week high of $107.62. The stock’s 50-day moving average is $95.15 and its two-hundred day moving average is $86.51. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44. The firm has a market cap of $8.76 billion, a P/E ratio of 39.22, a price-to-earnings-growth ratio of 1.78 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.13. The company had revenue of $354.64 million during the quarter, compared to the consensus estimate of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The company’s revenue for the quarter was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, analysts anticipate that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HQY has been the topic of a number of research analyst reports. Royal Bank Of Canada boosted their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Citizens Jmp increased their target price on shares of HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research report on Monday, June 1st. Wall Street Zen lowered shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. KeyCorp restated an “overweight” rating on shares of HealthEquity in a report on Tuesday, May 26th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of HealthEquity in a research note on Monday, June 1st. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.93.

HealthEquity Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.